Sustained Release Oral Formulation for Treatment of Parkinson's Disease
Status:
Not yet recruiting
Trial end date:
2023-08-02
Target enrollment:
Participant gender:
Summary
Achieving sustained blood levels of carbidopa/levodopa has been a challenge in the treatment
of PD and although levodopa remains the most commonly used drug, motor fluctuations remain a
major disability especially in advanced Parkinson's disease. The aim of this study is to
determine the efficacy of a novel oral carbidopa-levodopa formulation in achieving a
sustained blood level of levodopa and carbidopa in PD.